cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-1-73-79cardiovascular-122Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMСОВРЕМЕННЫЕ РЕКОМЕНДАЦИИ ПО СТРАТИФИКАЦИИ РИСКА И ПРОФИЛАКТИКЕ ВНЕЗАПНОЙ СЕРДЕЧНОЙ СМЕРТИ У БОЛЬНЫХ ГИПЕРТРОФИЧЕСКОЙ КАРДИОМИОПАТИЕЙ (ПО МАТЕРИАЛАМ РЕКОМЕНДАЦИЙ АМЕРИКАНСКОГО КОЛЛЕДЖА КАРДИОЛОГИИ/ АМЕРИКАНСКОЙ АССОЦИАЦИИ СЕРДЦА 2011)CURRENT RECOMMENDATIONS ON RISK STRATIFICATION AND SUDDEN CARDIAC DEATH PREVENTION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (BASED ON THE 2011 RECOMMENDATIONS BY THE AMERICAN COLLEGE OF CARDIOLOGY / AMERICAN HEART ASSOCIATION)ПриваловаЕ. В.PrivalovaE. V.

д.м.н., проф. кафедры госпитальной терапии № 1 лечебного факультета

Тел.: 8–903–681–96–98 

ev_privalova@mail.ruКаплуноваВ. Ю.KaplunovaV. Yu.

д.м.н., гл.н.с.

ХабароваН. В.KhabarovaN. V.

к.м.н., ст.н.с.

ШакарьянцГ. А.ShakaryantsG. A.

аспирант кафедры госпитальной терапии № 1 лечебного факультета

БеленковЮ. Н.BelenkovYu. N.

д.м.н., проф., член-корр. РАН, академик РАМН, зав. кафедрой госпитальной терапии № 1 лечебного факультета

ГБОУ ВПО Первый московский государственный медицинский университет имени И.М. СеченоваI.M. Sechenov First Moscow State Medical UniversityНаучно-исследовательский отдел НОК центр “Метаболический синдром” НИЦ Минздрава России, МоскваMetabolic Syndrome Research Centre, Moscow2013200220131217379Copyright © Привалова Е.В., Каплунова В.Ю., Хабарова Н.В., Шакарьянц Г.А., Беленков Ю.Н., 20132013Привалова Е.В., Каплунова В.Ю., Хабарова Н.В., Шакарьянц Г.А., Беленков Ю.Н.Privalova E.V., Kaplunova V.Y., Khabarova N.V., Shakaryants G.A., Belenkov Y.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/122

Одним из вариантов течения гипертрофической кардиомиопатии (ГКМП) является внезапная сердечная смерть (ВСС). Стратификация риска развития ВСС является важнейшим этапом в определении тактики ведения больного ГКМП. Своевременное назначение профилактической терапии больным с высоким риском ВСС является единственным способом спасти их жизнь. Клинический опыт свидетельствует о том, что стратификация риска ВСС является достаточно эффективным алгоритмом для решения вопроса о необходимости проведения профилактического лечения, которое должно быть индивидуально в зависимости от уровня риска каждого больного. 

One of the clinical scenarios of hypertrophic cardiomyopathy (HCMP) is sudden cardiac death (SCD). The stratification of SCD risk is the key component of defining the therapeutic strategy in HCMP patients. Timely preventive treatment is the only life-saving intervention in patients with high SCD risk. The available clinical evidence suggests that SCD risk stratification is an effective algorithm for determining the need for preventive treatment. The latter should be individualised, based on the risk levels in each patient. 

гипертрофическая кардиомиопатиястратификация риска внезапной сердечной смертипрофилактика внезапной сердечной смертикардиовертер-дефибрилляторhypertrophic cardiomyopathystratification of sudden cardiac death risksudden cardiac death risk preventioncardioverter defibrillatorReferencesMaron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006;113:1807–16.Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006;113:1807–16.Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes. Circulation 2007; 115: 1643–55.Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes. Circulation 2007; 115: 1643–55.A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24: 1965–91.A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24: 1965–91.A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC 2011; 25: e212–60.A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC 2011; 25: e212–60.Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405–12.Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405–12.Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374–450.Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374–450.Elliott PE, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. JACC 2000; 36: 2212–8.Elliott PE, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. JACC 2000; 36: 2212–8.Coats CJ, Elliott PM. Current management of hypertrophic cardiomyopathy. Curr Treat Options Cardiovasc Med 2008; 10 (6): 496–504.Coats CJ, Elliott PM. Current management of hypertrophic cardiomyopathy. Curr Treat Options Cardiovasc Med 2008; 10 (6): 496–504.Morales A, Cowan J, Dagua J, et al. Family history: an essential tool for cardiovascular genetic medicine. Congest Heart Fail 2008; 14 (1): 37–45.Morales A, Cowan J, Dagua J, et al. Family history: an essential tool for cardiovascular genetic medicine. Congest Heart Fail 2008; 14 (1): 37–45.Prasad K, Williams L, Campbell R, et al. Episodic syncope in hypertrophic cardiomyopathy: evidence for inappropriate vasodilation. Heart 2008; 94 (10): 1312–7.Prasad K, Williams L, Campbell R, et al. Episodic syncope in hypertrophic cardiomyopathy: evidence for inappropriate vasodilation. Heart 2008; 94 (10): 1312–7.Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace 2007; 9 (9): 817–22.Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace 2007; 9 (9): 817–22.Cotiga D, Ehlert F, Sherrid M. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy. Anadolu Kardiyol Derg 2006;6 Suppl 2: 55–60.Cotiga D, Ehlert F, Sherrid M. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy. Anadolu Kardiyol Derg 2006;6 Suppl 2: 55–60.Pezawas T, Stix G, Kastner J, et al. Implantable loop recorder in unexplained syncope: classification, mechanism, transient loss of consciousness and role of major depressive disorder in patients with and without structural heart disease. Heart 2008; 94 (4): e17.Pezawas T, Stix G, Kastner J, et al. Implantable loop recorder in unexplained syncope: classification, mechanism, transient loss of consciousness and role of major depressive disorder in patients with and without structural heart disease. Heart 2008; 94 (4): e17.Maron BJ, Piccininno M, Bernabo P, et al. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol 2003; 91: 626–8.Maron BJ, Piccininno M, Bernabo P, et al. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol 2003; 91: 626–8.Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778–85.Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778–85.Elliott PE, Gimeno Blanes JR, Mahon NG, et al. Relation between the severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420–4.Elliott PE, Gimeno Blanes JR, Mahon NG, et al. Relation between the severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420–4.Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. JACC 2000; 36: 2212–8.Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. JACC 2000; 36: 2212–8.Cha YM, Gersh BJ, Maron BJ, et al. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2007; 18 (5): 483–7.Cha YM, Gersh BJ, Maron BJ, et al. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2007; 18 (5): 483–7.Maron BJ, Shen W-K, Link MS, et al. Efficacy of the implantable cardioverter-defibrillators for the prevention of deaths in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365–73.Maron BJ, Shen W-K, Link MS, et al. Efficacy of the implantable cardioverter-defibrillators for the prevention of deaths in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365–73.Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27 (16): 1933–41.Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27 (16): 1933–41.Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age￾dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy. JACC 2002; 39: 2042–8.Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age￾dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy. JACC 2002; 39: 2042–8.Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118: 1541–9.Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118: 1541–9.Margos PN, Schomburg R, Kynast J, et al. Termination of Ventricular Tachycardia with Antitachycardia Pacing after Ineffective Shock Therapy in an ICD Recipient with Hypertrophic Cardiomyopathy. Indian Pacing Electrophysiol J 2009; 9 (1): 64–70.Margos PN, Schomburg R, Kynast J, et al. Termination of Ventricular Tachycardia with Antitachycardia Pacing after Ineffective Shock Therapy in an ICD Recipient with Hypertrophic Cardiomyopathy. Indian Pacing Electrophysiol J 2009; 9 (1): 64–70.Sherrid MV, Daubert JP. Risks and challenges of implantable cardioverter-defibrillators in young adults. Prog Cardiovasc Dis 2008; 51 (3): 237–63.Sherrid MV, Daubert JP. Risks and challenges of implantable cardioverter-defibrillators in young adults. Prog Cardiovasc Dis 2008; 51 (3): 237–63.Przybylski A, Małecka L, Pytkowski M, et al. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy — dilemmas and difficulties. Kardiol Pol 2005; 63 (4): 391–7.Przybylski A, Małecka L, Pytkowski M, et al. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy — dilemmas and difficulties. Kardiol Pol 2005; 63 (4): 391–7.Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–83.Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–83.Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008; 19 (10): 1118–26.Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008; 19 (10): 1118–26.Maron BJ, Estes NAM III, Maron MS, et al. Primary prvention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003; 107: 2872–5.Maron BJ, Estes NAM III, Maron MS, et al. Primary prvention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003; 107: 2872–5.Maron BJ, Maron MS, Lesser JR, et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 2008; 101 (4): 544–7.Maron BJ, Maron MS, Lesser JR, et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 2008; 101 (4): 544–7.Elliott P. Investigation and treatment of hypertrophic cardiomyopathy. Clin Med 2007; 7 (4): 383–7.Elliott P. Investigation and treatment of hypertrophic cardiomyopathy. Clin Med 2007; 7 (4): 383–7.Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. JACC 2005; 45: 1340–5.Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. JACC 2005; 45: 1340–5.Pelliccia A, Fagard R, Bjornstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 1422–45.Pelliccia A, Fagard R, Bjornstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 1422–45.Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064–75.Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064–75.Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation 2009; 119: 1085–92.Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation 2009; 119: 1085–92.

The authors declare that there are no conflicts of interest present.